Knowledge of donor and recipient (D/R) cytomegalovirus (CMV) serostatus is critical for risk stratification of CMV infection and disease in transplant recipients, particularly in the solid organ transplantation (SOT) setting. Despite its broad availability and the success of it use, the risk stratification based on the D/R serostatus is not free of limitations since there are a nondepreciable number of patients that are not accurately categorized by this approach. In fact, up to 20% of seropositive SOT recipients, classically considered at intermediate risk, develop episodes of CMV infection and disease after transplantation. Here, we provide an overview of additional donor and recipient factors that may have utility in identifying patients at risk for post-transplant CMV infection. Specifically, we summarize our current understanding regarding the potential use of use CMV-specific T-cell-mediated immunity, neutralizing antibodies and host genetics that may influence the risk of CMV infection and disease. We provide an overview of the benefits and limitations associated with using these immunological factors in risk stratification and propose specific variables that could be analyzed at the pretransplant evaluation to improve the identification of patients with increased individual susceptibility.
| INTRODUCTION
Human cytomegalovirus (CMV) is a highly cytopathogenic virus that continues to be one of the major causes of morbidity and mortality in solid organ transplant (SOT) and allogeneic hematopoietic stem-cell transplant (allo-HSCT) recipients. In addition, growing evidence supports the deleterious role of CMV infection on both patient and graft outcomes through the so-called indirect immunomodulatory effects (Table 1) . [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Recent evidence has also highlighted the protective role of antibodies targeting the viral pentameric complex gH/gL/pUL128-131A. 13 The presence in serum of some of the nonneutralizing antibodies against CMV proteins elicited upon infection, such as pp65, pp150, pp28, or pp52 among others, 14 is used to determine the serological status.
In addition, cytokines, such as interleukin (IL)-2, secreted by CD4 + T-cells can also lead to the proliferation of CD8 + T-cells. Activated CD4 + T-cells can be also involved in blocking intracellular virus by inducing the suppression of virus replication through the secretion of IFN-γ ( Figure 1 ).
Hereafter, specific clinical and immunological variables that influence the susceptibility to CMV infection in the setting of SOT and allo-HSCT will be separately reviewed in each of the sections.
1. SOT setting: CMV is efficiently transmitted through organ transplantation, and such risk increases in the absence of preexisting CMV-specific immunity in the recipient and with the amount of lymphoid tissue in the graft. 15, 16 In addition, the long-term immunosuppression required to prevent graft rejection poses an Historical data on the natural course of CMV infection confirmed that the incidence of CMV disease is almost 3 times higher for D + /R − patients compared with R + groups (56% versus 20%, respectively). 19 Although the individual susceptibility to CMV infection is further modulated by various factors (such as the type of transplant, the administration of T-cell depleting agents, immunosuppression, or other coinfections), 17 risk stratification according to the D/R serological status is the cornerstone on which current approaches to minimize the deleterious impact of this pathogen are based. In accordance, consensus guidelines strongly recommend testing for anti-CMV immunoglobulin G (IgG) antibodies before SOT in both donor and recipients. 20 However, a Increased susceptibility to bacterial and opportunistic infections (including invasive fungal disease) 5, 9 Increased incidence of EBV-related PTLD 7 Acute graft rejection and graft loss in kidney transplantation 10 Increased cardiovascular risk and occurrence of atherothrombotic events in kidney transplantation 3 Chronic allograft vasculopathy in heart transplantation 4 Chronic lung allograft dysfunction (bronchiolitis obliterans syndrome) in lung transplantation 8 Accelerated recurrence of HCV liver disease in liver transplantation 2 Increased incidence of GVHD in aHSCT 1 Decreased overall and non-relapse survival in aHSCT Thus, the present review is aimed at providing a comprehensive synthesis of the literature benefits and limitations associated with using the combination of D/R serological status to CMV for risk stratification in both the SOT and the allo-HSCT populations and propose specific variables that could be analyzed pretransplantation to improve the identification of patients at risk for infection.
| Is pretransplant serostatus an accurate predictor of risk for CMV infection?
Since the serology test measures the presence of antibodies against viral proteins in serum, which is indicative of a previous infection, it which is usually considered as the reference technique to quantify the CMV-specific cell-mediated immunity (CMI), 25 we found that 77.6% of R + patients lack detectable pretransplant T-cell response. 26 In addition, up to 20% of R + SOT recipients, conven- The negative impact on overall survival of receiving an allograft from a CMV-seronegative donor was recently confirmed and appeared to be directly related to CMV-associated outcomes, namely increased incidence of recurrent episodes of active CMV infection (in particular those requiring the initiation of antiviral therapy) and late end-organ disease. Nevertheless, this detrimental effect was only observed for those patients undergoing myeloablative conditioning. 6 In contrast, data from an EBMT study specifically focused on patients with de novo acute leukemia failed to support this assumption. 33 In any case, the accurate determination of D/R CMV serostatus prior to allo-HSCT is of major relevance. In a recent study, Perry and Hakki noted that allo-HSCT recipients may be miscategorized as being CMV seropositive if serological testing is performed after receipt of blood transfusions or when employing assays with suboptimal specificity. 34 Recently, Loeth et al found CD4 + and/or CD8 + pp65-specific T-cell responses in five out of 44 seronegative individuals. This number was increased to 34 (77%) after 7 days of in vitro stimulation. 35 Together these results suggest that the serology test, although it is undoubtedly useful in some contexts, could be implemented with other pretransplant variables to assure the most accurate prediction of CMV infection risk and recipient outcomes after transplantation, especially for those patients in which serology shows some limitations (Figure 2 ).
1.2 | Does CMV-specific cell-mediated immunity have clinical utility for risk stratification?
Other variables, such as CMV-specific CMI, have been explored as a means for stratifying the risk of CMV-infection after transplantation.
Most of the published literature in this area has explored the role of CMV-specific CMI in the post-transplant period. However, we provide herein an overview of available results when such assessment is performed at the baseline (ie, pretransplant) evaluation. 
| Do neutralizing antibody titers provide information regarding the risk for CMV infection?
a. SOT setting: In addition to the promising data demonstrating the clinical utility of assessing CMI for risk stratification, there is still a nonnegligible percentage of SOT recipients (ranging from 4 to 10%) with demonstrable and apparently protective CMVspecific CMI responses that develop late-onset disease. 31, 43 This observation suggests that either a higher cut-off may be necessary for defining a positive CMV-specific CMI response to assure that it reliably predicts protection against CMV disease, or that other arms of the immune response should also be considered.
In the past, different randomized clinical trials demonstrated that the administration of CMV-specific hyperimmune globulin reduced the incidence of CMV disease in liver and renal transplant recipients. 44 , 45 The results of a meta-analysis analyzing 698 SOT recipients demonstrated that the administration of hyperimmune globulin improved overall survival and reduced the incidence of CMV disease and CMV-associated mortality. 46 In fact, hypogammaglobulinemia (HGG), that it is common among transplant recipients receiving immunosuppressive regimens, 47 has been recognized as a risk factor for post-transplant CMV disease. A retrospective analysis of liver recipients included in a clinical trial evaluating the effect of CMV-specific hyperimmune globulin prophylaxis on the prevention of disease and its complications suggested that HGG was associated to both the occurrence and the relapse of CMV disease after transplantation. 48 The results from a meta-analysis suggested that severe IgG HGG significantly increases the risk of CMV infection and is associated with higher 1-year all-cause mortality. 47 A recent cohort study of heart transplant recipients demonstrated that the presence of IgG HGG at 7 days after transplantation is a risk factor for CMV disease. 48 In addition, in a clinical trial the administration of two monoclonal antibodies in R − kidney recipients at the time of transplant and 1, 4, and 8 post-transplant weeks reduced the incidence of CMV infection, increased the time interval to CMV viremia and was associated with less CMV disease. 49 More recently, early monitoring of specific humoral immunity parameters was proven to be useful for the identification of lung recipients who are at risk of serious infections. 50 All these data together has renewed the interest in studying the role of neutralizing antibodies against CMV infection.
Neutralizing antibodies directed against epitopes of the pentameric complex consisting of gH/gL/pUL128-130-131A have demonstrated potent in vitro neutralizing activity against CMV. 51 In fact, the pentameric complex is necessary for in vitro infection of epithelial and endothelial cells but not fibroblasts. 52 Gerna et al demonstrated in healthy individuals with primary and reactivated infection FIGURE 2 Variables that can be implemented pretransplantation to assure the most accurate prediction of cytomegalovirus (CMV) disease risk and recipient outcomes after transplantation. Detection of cell-mediated immunity, neutralizing antibodies, levels of immunoglobulins, and nucleotide variations in genes related to virus specific immunity can be used pretransplantation to determine postransplantation risk of infection and disease, implementing the current serological methods that levels of neutralizing antibody able to block infection of endothelial (or epithelial) cells were higher and able to inhibit CMV plaque formation and virus transfer from CMV-infected cells to leukocytes. 
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Although there is no evidence of CMV-specific neutralizing antibody activity in the allo-HSCT setting, the available data support the idea that testing levels of neutralizing antibodies at the pretransplant evaluation may be a useful tool for predicting CMV-related outcomes after transplantation. Therefore, studies measuring pretransplantation neutralizing antibody levels could be warranted in certain clinical scenarios.
| Does the recipient's genetic background predispose to active infection after transplantation?
In On the basis of these results, different studies have identified MBL2 alleles that confer higher risk of CMV infection and disease after SOT. [58] [59] [60] On the other hand, certain TLRs (particularly TLR2, TLR4, and TLR9) have been shown to be involved in antiviral immunity. Homozygosity for TLR2 R753Q was described as a risk marker for CMV disease, especially tissue-invasive forms, after liver transplantation. 61 The D299G and T399I positions of the TLR4 gene were associated with higher risk of CMV disease in kidney transplant recipients. 62 Additionally, R + kidney transplant recipients with the TLR9 (rs5743836) SNP had lower incidence of CMV infection. 63 An A-to-C SNP within the 3'-untranslated region (3'UTR) of the IL-12p40 gene was reported as a new risk factor for CMV reactivation and for the occurrence of CMV infection after kidney transplantation. 64 In addition, D + /R − patients with an IL-28B SNP (rs8099917) had significantly lower levels of CMV replication, 65 while R + kidney recipients carrying the T allele of the rs12979860 SNP were less susceptible to CMV infection than their CC counterparts.
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The IFN-γ + 874 T/T genotype, associated with high levels of IFN-γ production, was found as an independent risk factor for developing CMV disease in heart recipients. were significantly associated with an increased risk of CMV reactivation and disease. 69 Carvalho et al found a significant association between the presence of the T-1237C polymorphism (TLR9) and the susceptibility to CMV. 70 Bravo et al investigated the donor or the recipient IL-28B SNP (rs12979860) genotype and found a trend towards a lower incidence of active CMV infection in the donor T/T population with respect to the donor C/T and C/C counterparts. Duration of first CMV DNAemia episodes was significantly shorter in patients carrying the donor T/T genotype. 71 It was later shown that the protective effect attributed to the rs12979860 SNP minor T allele could be mediated, at least in part, by eliciting robust CMV-specific T-cell responses. 72 Taken together, these results suggest that testing transplant patients for the presence of certain SNPs may thus be useful for individualizing antiviral prophylaxis in this context. However, it should be emphasized that these proposals for improved risk stratification are merely theory generating, since most of the assays are currently in experimental phase and may not be still transferable to clinical practice. In addition, it would be necessary to standardize and define the optimal cut-offs across different population Table 1) . 75 In addition, the cost-effectiveness should be ideally evaluated by taking into account the cost of additional immunological determinations and the expected variation in the consumption of antiviral prophylaxis or therapy. In our opinion, the strategies proposed in Figure 2 should be regarded as essentially conservative in view of the suggestions given for (val) ganciclovir prophylaxis, and alternative immune-guided interventions would be also possible. 
| Practical suggestions for risk stratification

